Brief: Elicio Therapeutics Reports Robust T Cell Responses Across Diverse HLA Backgrounds In Ongoing Phase 2 Amplify-7P Trial
27/10/2025 13:27
Oct 27 (Reuters) - Elicio Therapeutics Inc ELTX.O: ELICIO THERAPEUTICS REPORTS ROBUST T CELL RESPONSES ACROSS DIVERSE HLA BACKGROUNDS IN ONGOING PHASE 2 AMPLIFY-7P TRIAL Source text: ID:nGNX3vlNrH Further company coverage: ELTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Elicio Therapeutics
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Elicio Therapeutics Q2 net loss narrows as R&D expenses fall
Elicio Therapeutics Inc expected to post a loss of 54 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Datadog, Terawulf, Paychex
Elicio shares slide after pancreatic cancer vaccine falls short in mid-stage study (updated)